Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Director | August 25, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date August 25, 2026 · Filed August 28, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,373 |
Last balance in matching sequence
After 2026-08-25 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-08-25 · Exercise / conversion · Acquired 1,402 · Balance 6,775 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. Row 2 · 2026-08-25 · Exercise / conversion · Acquired 1,740 · Balance 8,515 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. Row 3 · 2026-08-25 · Sale · Disposed 694 · Balance 7,821 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Row 4 · 2026-08-25 · Sale · Disposed 646 · Balance 7,175 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Row 5 · 2026-08-25 · Sale · Disposed 1,802 · Balance 5,373 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2027-09-17 | Direct | 2,803 |
Reported balance
After 2026-08-25 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2026-08-25 · Exercise / conversion · Acquired 1,402 · Balance 2,803 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F2: On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2028-08-08 | Direct | 3,480 |
Reported balance
After 2026-08-25 transaction · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · 2026-08-25 · Exercise / conversion · Acquired 1,740 · Balance 3,480 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F3: On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.
F2: On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.
F3: On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Raptor Pharmaceutical Corp
Report date October 24, 2016 · Filed October 26, 2016
Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-10-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-24 · Other · Disposed 6,695 · Balance 8,330 F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Row 2 · 2016-10-25 · Disposition to issuer · Disposed 8,330 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2020-10-12 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-25 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2020-11-22 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-10-25 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2021-09-22 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-10-25 · Disposition to issuer · Disposed 120,000 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.49 · Expires 2022-09-25 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-10-25 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2026 Filed Aug 27, 2026 22:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 1,802 | $113.05 | $203,716.10 |
DisclosureSEC source: 0001437749-26-029115 · rdgdoc.xml · nonDerivative · entry 3 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 22:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 646 | $110.07 | $71,105.22 |
DisclosureSEC source: 0001437749-26-029115 · rdgdoc.xml · nonDerivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,523 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 22:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 694 | $110.04 | $76,367.76 |
DisclosureSEC source: 0001437749-26-029115 · rdgdoc.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,169 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document |
| August 25, 2026 Filed Aug 28, 2026 23:41 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionStock Option · Derivative | 1,740 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001437749-26-029228 · rdgdoc.xml · derivative · entry 7 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,480 Underlying: Common Stock · 1,740 shares Expires 2028-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F3 · derivative.exercise_date: On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020. Read SEC document |
| August 25, 2026 Filed Aug 28, 2026 23:41 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionStock Option · Derivative | 1,402 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001437749-26-029228 · rdgdoc.xml · derivative · entry 6 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,803 Underlying: Common Stock · 1,402 shares Expires 2027-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F2 · derivative.exercise_date: On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter. Read SEC document |
| August 25, 2026 Filed Aug 28, 2026 23:41 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 1,802 | $113.05 | $203,716.10 |
DisclosureSEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 5 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,373 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Read SEC document |
| August 25, 2026 Filed Aug 28, 2026 23:41 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 646 | $111.07 | $71,751.22 |
DisclosureSEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 4 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,175 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Read SEC document |
| August 25, 2026 Filed Aug 28, 2026 23:41 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 694 | $110.04 | $76,367.76 |
DisclosureSEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 3 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,821 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Read SEC document |
| August 25, 2026 Filed Aug 28, 2026 23:41 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,740 | $30.00 | $52,200.00 |
DisclosureSEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. Read SEC document |
| August 25, 2026 Filed Aug 28, 2026 23:41 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,402 | $30.00 | $42,060.00 |
DisclosureSEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:48 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 2,924 | $0.00 Strike: $75.94 | $0.00 |
DisclosureSEC source: 0001437749-25-037168 · rdgdoc.xml · derivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,924 Underlying: Common Stock · 2,924 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026 Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 00:55 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 11,365 | $0.00 Strike: $31.70 | $0.00 |
DisclosureSEC source: 0001437749-25-006725 · rdgdoc.xml · derivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,365 Underlying: Common Stock · 11,365 shares Expires 2035-03-04 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025 Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000488 · rdgdoc.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-000488 · rdgdoc.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-027582 · rdgdoc.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,533 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-027582 · rdgdoc.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:50 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019262 · rdgdoc.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,066 Underlying: Common Stock · 2,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:50 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019262 · rdgdoc.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:18 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009334 · rdgdoc.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:18 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-009334 · rdgdoc.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 10,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002520 · rdgdoc.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,133 Underlying: Common Stock · 10,133 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 13,930 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001437749-23-002520 · rdgdoc.xml · derivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,930 Underlying: Common Stock · 13,930 shares Expires 2033-02-01 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:11 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000173 · rdgdoc.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:11 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000173 · rdgdoc.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013276 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-013276 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009142 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,718 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-009142 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-004479 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-004479 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 11,436 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-001169 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,436 Underlying: Common Stock · 11,436 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 15,128 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001654954-22-001169 · section16.xml · derivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,128 Underlying: Common Stock · 15,128 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 18:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000121 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 18:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000121 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-010717 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-010717 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:18 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 752 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007604 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,502 Underlying: Common Stock · 752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:18 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-007604 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 23:41 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-003789 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,254 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 23:41 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-003789 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:57 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000921 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Underlying: Common Stock · 3,005 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:57 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 4,443 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001654954-21-000921 · section16.xml · derivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Underlying: Common Stock · 4,443 shares Expires 2031-01-25 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 322 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000148 · section16.xml · derivative · entry 4 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000148 · section16.xml · nonDerivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 22:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 322 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000148 · section16.xml · derivative · entry 3 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 22:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000148 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-007304 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644 Underlying: Common Stock · 323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-20-007304 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 18:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 322 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-003675 · section16.xml · derivative · entry 2 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 18:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-20-003675 · section16.xml · nonDerivative · entry 1 Anderson Raymond · CIK 0001362489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.